We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Tripos, a leading provider of drug discovery chemistry and informatics products
and services, and BioTie Therapies, a Finnish biotech company, have announced
a partnership to enhance BioTie's drug discovery efforts, which include innovative
medicines for the treatment of dependence disorders, inflammatory diseases and
thrombosis.
The Institute for the Study of Aging (ISOA), a biomedical venture philanthropy
created to catalyze and fund drug discovery research for Alzheimer's disease,
recently awarded a two-year program-related investment to NeuroMolecular Pharmaceuticals
(NeuroMolecular).
Barrier Therapeutics, a pharmaceutical company developing products in the field
of dermatology, has announced the acquisition of the U.S. and Canadian rights
to Solage (mequinol 2 percent, tretinoin 0.01 percent) Topical Solution from
Moreland Enterprises.
Beyond Genomics has announced its name change to BG Medicine. The company also
announced the appointment of Pieter Muntendam as its new president to lead the
company's business operations and strategy.
Japan's largest drugmaker, Takeda Pharmaceutical,
will acquire Syrrx, a privately held California biotechnology company working
on treatments for cancer and diabetes, for roughly US$270 million in cash.
GlaxoSmithKline's (GSK) long-running feud with the IRS heated up when the tax
agency slapped the company with a nearly $2 billion bill for back taxes allegedly
owed by legacy company Glaxo Wellcome.
A federal appeals court recently voted to invalidate Merck's patent on its blockbuster
osteoporosis treatment Fosamax, clearing the way for generic firms to hone in
on the multibillion dollar market for the drug.
The FDA currently can approve drugs for either prescription or OTC use, but
a third "behind-the-counter" (BTC) alternative has gained notice in
recent weeks, as lawmakers seek ways to prevent the abuse of common OTC drugs
and drugmakers run into hurdles trying to switch their Rx products to OTC status.